Invivo Theraptc Cmn (NVIV) 6.72 $NVIV InVivo Th
Post# of 273254
Posted On: 09/24/2016 7:02:48 PM
Invivo Theraptc Cmn (NVIV) 6.72 $NVIV
InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting
BusinessWire - Tue Sep 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of Toronto, will give a late-breaking oral presentation titled "Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial" at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an oral presentation.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting
BusinessWire - Wed Sep 14, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled "High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury (SCI): Potential Mechanisms" at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting to be held September 24-28, 2016 in San Diego, CA. The presentation will be made on Tuesday, September 27, during the section on Neurotrauma and Critical Care.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 55th International Spinal Cord Society Annual Scientific Meeting
BusinessWire - Wed Sep 07, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President of Clinical Operations & Project Management, is scheduled to present at the 55th International Spinal Cord Society (ISCoS) Annual Scientific Meeting to be held September 14-16, 2016 in Vienna, Austria. Ms. Neff was invited to present along with several other leaders in the field of spinal cord injury clinical research on September 14 during the symposium titled "Clinical Trials Update for 2016." The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to provide an update on current clinical research to foster communication between researchers and clinicians on advancements and challenges in clinical research.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Participate in Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced that the company will participate in two upcoming investor conferences.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study
BusinessWire - Thu Aug 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Northwestern Medicine in Chicago, IL has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at the Northwestern Memorial Hospital, an 894-bed Level I trauma center.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer
BusinessWire - Thu Aug 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Pamela Stahl to the newly-created position of Chief Commercial Officer (CCO), effective September 14, 2016. In this role, she will be responsible for building a comprehensive global commercial strategy that includes developing the company's sales, reimbursement, and marketing strategies across key market segments to ensure a clear path for growth.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update
BusinessWire - Thu Aug 04, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2016.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society
BusinessWire - Thu Jun 23, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo's Senior Director of Research, will be giving a poster presentation at the National Neurotrauma Society (NNS) 2016 Symposium to be held June 26-29 in Lexington, KY. The abstract, titled "Biodegradable Neuro-Spinal Scaffold Promotes Neuropermissive Tissue Remodeling Following Spinal Contusion Injury in Rats" will be published electronically in the Journal of Neurotrauma immediately prior to the conference.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors
BusinessWire - Wed Jun 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Featured on CBS Radio Affiliate
BusinessWire - Thu May 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS - Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry. The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold(TM)
BusinessWire - Wed May 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo's Neuro-Spinal Scaffold(TM), which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims in previously granted U.S. Patent No. 9,101,695 issued on August 11, 2015 and U.S. Patent No. 8,858,966 issued on October 14, 2014. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study
BusinessWire - Wed May 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Hospital of the University of Pennsylvania (HUP), a part of the University of Pennsylvania Health System in Philadelphia, PA, has been added as a clinical site for The INSPIRE Study.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update
BusinessWire - Fri May 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016.
NVIV: 6.72 (-0.16)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.72 (-0.16), OGXI: 0.51 (+0.02), SEED: 2.30 (+0.12), TCS: 5.09 (+0.07)
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold(TM) in the INSPIRE Study
BusinessWire - Tue Apr 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications
BusinessWire - Wed Apr 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is "Neuro Devices and Neuro Regeneration".
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE Study
BusinessWire - Wed Feb 03, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County. Joseph Ciacci, M.D., Clinical Professor of Surgery at the UC San Diego School of Medicine and Chief of Neurosurgery at the Veteran Affairs San Diego Healthcare System, has been named Principal Investigator at the site.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 8th Annual Biotech Showcase
BusinessWire - Tue Jan 05, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual Biotech Showcase to be held January 11-13, 2016 in San Francisco, CA. The company's presentation will be Monday, January 11 at 3:30 PM (PST). A live webcast will be available at http://edge.media-server.com/m/p/om4nkdg5, and a webcast replay will be available at the same address approximately 2 hours after the live webcast presentation.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the Neuro-Spinal Scaffold(TM)
BusinessWire - Mon Jan 04, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced that it has received approval of a protocol amendment from the U.S. Food and Drug Administration (FDA) that will convert its ongoing pilot study into a pivotal probable benefit study. Prior to this announcement, the approval was conditional solely upon a minor change to the informed consent form.
NVIV: 6.72 (-0.16)
Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries
ACCESSWIRE - Tue Dec 15, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 15, 2015 / As 2015 winds to a close, a little reflection shows it was a huge year for biotechnology. Of course, this year featured the biggest tax inversion deal ever with Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) agreeing to combine companies in a whopping $160 billion deal. That mega-merger pushed the total for health and pharmaceutical mergers over $550 billion in 2015, up 17 percent from a year earlier, as big pharmas look to buy companies rather than risking resources on their own research and development. As with every year before it, 2015 was a time for new drugs to come to market, including Novartis' (NYSE: NVS) heart failure drug Entresto, and clinical trials advancing to offer hope for those in need in the future. Below are some companies that will be initiating key trials in 2016.
AGN: 243.94 (+0.51), SYN: 1.75 (-0.02), NVIV: 6.72 (-0.16), PFE: 34.26 (+0.11), NVS: 81.48 (-0.55)
InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting
BusinessWire - Tue Sep 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of Toronto, will give a late-breaking oral presentation titled "Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial" at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an oral presentation.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting
BusinessWire - Wed Sep 14, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled "High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury (SCI): Potential Mechanisms" at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting to be held September 24-28, 2016 in San Diego, CA. The presentation will be made on Tuesday, September 27, during the section on Neurotrauma and Critical Care.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 55th International Spinal Cord Society Annual Scientific Meeting
BusinessWire - Wed Sep 07, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President of Clinical Operations & Project Management, is scheduled to present at the 55th International Spinal Cord Society (ISCoS) Annual Scientific Meeting to be held September 14-16, 2016 in Vienna, Austria. Ms. Neff was invited to present along with several other leaders in the field of spinal cord injury clinical research on September 14 during the symposium titled "Clinical Trials Update for 2016." The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to provide an update on current clinical research to foster communication between researchers and clinicians on advancements and challenges in clinical research.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Participate in Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced that the company will participate in two upcoming investor conferences.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study
BusinessWire - Thu Aug 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Northwestern Medicine in Chicago, IL has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at the Northwestern Memorial Hospital, an 894-bed Level I trauma center.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer
BusinessWire - Thu Aug 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Pamela Stahl to the newly-created position of Chief Commercial Officer (CCO), effective September 14, 2016. In this role, she will be responsible for building a comprehensive global commercial strategy that includes developing the company's sales, reimbursement, and marketing strategies across key market segments to ensure a clear path for growth.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update
BusinessWire - Thu Aug 04, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2016.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society
BusinessWire - Thu Jun 23, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo's Senior Director of Research, will be giving a poster presentation at the National Neurotrauma Society (NNS) 2016 Symposium to be held June 26-29 in Lexington, KY. The abstract, titled "Biodegradable Neuro-Spinal Scaffold Promotes Neuropermissive Tissue Remodeling Following Spinal Contusion Injury in Rats" will be published electronically in the Journal of Neurotrauma immediately prior to the conference.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors
BusinessWire - Wed Jun 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Featured on CBS Radio Affiliate
BusinessWire - Thu May 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS - Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry. The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold(TM)
BusinessWire - Wed May 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo's Neuro-Spinal Scaffold(TM), which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims in previously granted U.S. Patent No. 9,101,695 issued on August 11, 2015 and U.S. Patent No. 8,858,966 issued on October 14, 2014. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study
BusinessWire - Wed May 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Hospital of the University of Pennsylvania (HUP), a part of the University of Pennsylvania Health System in Philadelphia, PA, has been added as a clinical site for The INSPIRE Study.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update
BusinessWire - Fri May 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016.
NVIV: 6.72 (-0.16)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.72 (-0.16), OGXI: 0.51 (+0.02), SEED: 2.30 (+0.12), TCS: 5.09 (+0.07)
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold(TM) in the INSPIRE Study
BusinessWire - Tue Apr 26, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications
BusinessWire - Wed Apr 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is "Neuro Devices and Neuro Regeneration".
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE Study
BusinessWire - Wed Feb 03, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County. Joseph Ciacci, M.D., Clinical Professor of Surgery at the UC San Diego School of Medicine and Chief of Neurosurgery at the Veteran Affairs San Diego Healthcare System, has been named Principal Investigator at the site.
NVIV: 6.72 (-0.16)
InVivo Therapeutics to Present at 8th Annual Biotech Showcase
BusinessWire - Tue Jan 05, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual Biotech Showcase to be held January 11-13, 2016 in San Francisco, CA. The company's presentation will be Monday, January 11 at 3:30 PM (PST). A live webcast will be available at http://edge.media-server.com/m/p/om4nkdg5, and a webcast replay will be available at the same address approximately 2 hours after the live webcast presentation.
NVIV: 6.72 (-0.16)
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the Neuro-Spinal Scaffold(TM)
BusinessWire - Mon Jan 04, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced that it has received approval of a protocol amendment from the U.S. Food and Drug Administration (FDA) that will convert its ongoing pilot study into a pivotal probable benefit study. Prior to this announcement, the approval was conditional solely upon a minor change to the informed consent form.
NVIV: 6.72 (-0.16)
Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries
ACCESSWIRE - Tue Dec 15, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 15, 2015 / As 2015 winds to a close, a little reflection shows it was a huge year for biotechnology. Of course, this year featured the biggest tax inversion deal ever with Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) agreeing to combine companies in a whopping $160 billion deal. That mega-merger pushed the total for health and pharmaceutical mergers over $550 billion in 2015, up 17 percent from a year earlier, as big pharmas look to buy companies rather than risking resources on their own research and development. As with every year before it, 2015 was a time for new drugs to come to market, including Novartis' (NYSE: NVS) heart failure drug Entresto, and clinical trials advancing to offer hope for those in need in the future. Below are some companies that will be initiating key trials in 2016.
AGN: 243.94 (+0.51), SYN: 1.75 (-0.02), NVIV: 6.72 (-0.16), PFE: 34.26 (+0.11), NVS: 81.48 (-0.55)
(0)
(0)Scroll down for more posts ▼